XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

TECHNOLOGY INVESTMENT AGREEMENT | 3 Months Ended
--- | ---
Mar. 31, 2024
TECHNOLOGY INVESTMENT AGREEMENT |
TECHNOLOGY INVESTMENT AGREEMENT | 7. TECHNOLOGY INVESTMENT AGREEMENT Effective July 1, 2020, the Company entered into the Technology Investment Agreement (TIA) with the U.S. government to expand the Company’s manufacturing capacity for hypodermic safety needles in response to the worldwide COVID-19 global pandemic. The award is an expenditure-type TIA, whereby the U.S. government has made payments to the Company for the Company’s expenditures for equipment and supplies related to the expansion. The Company’s contributions under the terms of the TIA include providing facilities, technical expertise, labor and maintenance for the TIA-funded equipment for a ten-year term. In May of 2021, the Company and the U.S. government amended the TIA agreement to include two additional assembly lines and additional controlled environment space. The Company has received all equipment, has completed all property construction required by the TIA, and all reimbursement requests have been submitted. No further amounts for expansion under the TIA are expected to be submitted or collected. At the request of the US government, the TIA was transferred to a successor agreement, identified as Other Transaction Agreement in April 2023. Such agreement contains no additional requirements, and, for the purposes of this report, the agreement shall continue to be referred to herein as the “TIA”. The successor agreement governs ongoing terms established by the TIA until June 30, 2030, which includes maintenance of equipment, availability of capacity, and US government preference in the event of a public health emergency. Under the TIA, reimbursable amounts are reflected as Other long-term liabilities on the Balance Sheets until the time the deferred income can be systematically amortized over a period matching the useful life of the purchased assets. Other long-term liabilities from the TIA were $68,288,918 and $74,439,649 at March 31, 2024 and 2023, respectively.

X
- References No definition available. + Details
Name: | rvp_TechnologyInvestmentAgreementDisclosureAbstract
Namespace Prefix: | rvp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for Technology Investment Agreement. + References No definition available. + Details
Name: | rvp_TechnologyInvestmentAgreementDisclosureTextBlock
Namespace Prefix: | rvp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration